MOTS-c in a dialysis blood test
The animal experiments invite optimism. The human blood measurement complicates my expectations.
Hemodialysis cohort findings
The multicentre MOTS-c cohort followed 94 people on chronic hemodialysis for a median of 26.5 months. Higher circulating MOTS-c was associated with the combined outcome of death from any cause and nonfatal cardiovascular events, even after adjustment for other measured health factors. Adding the peptide measurement improved the study’s risk prediction.
That last finding is useful in a very particular sense: the measurement helped distinguish people more likely to reach the outcome. The study observed a concentration; it never tested giving people the peptide. A target for treatment would outrun the cohort’s design.
The direction of the association matters, too. Someone arriving from the mouse performance papers might expect more MOTS-c to mean better health. This cohort offers a direct objection to that expectation. The results concern people with severe kidney disease, and the explanation for the association remains open.
Where MOTS-c comes from
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Mitochondria produce cellular energy, but their genetic instructions also include this small signaling peptide. That origin explains some of the fascination: the cell’s energy machinery can send messages beyond its usual work.
In human and mouse cell experiments under metabolic stress, MOTS-c moved into the nucleus, where most cellular DNA is housed, and affected stress-responsive gene activity. AMPK, a protein involved in sensing cellular energy, was required for the response. These were experiments in cells. I admire this mitochondrial ingenuity; a human health benefit will need human treatment evidence.
Mouse muscle experiments with MOTS-c
The physical-performance study gave MOTS-c to young, middle-aged and old mice. Running capacity improved, alongside other physical-performance findings. Exercise also induced the peptide in mouse muscle and circulation. The experiment makes a plausible case for studying its role in muscle adaptation.
A separate CK2 study in mice and cell-free assays identified a protein that MOTS-c binds directly: casein kinase 2. Its activity rose in muscle and fell in fat, with increased muscle glucose uptake and protection against atrophy in the experiments. Atrophy is the shrinking of muscle.
The distinction between these experiments and the dialysis cohort is fundamental. The experiments changed exposure and watched what followed in animals or assays. The cohort watched a naturally occurring blood measurement in people. Each can be informative without resolving the other.
Human exposure uncertainties
The MOTS-c review brings together work on stress, metabolism and aging. The human evidence discussed here remains observational. These sources establish no completed human treatment trial showing that extra MOTS-c improves metabolism, performance or longevity, and they provide no dependable human side-effect rates.
The current record also lacks a validated human treatment half-life, bioavailability or dose-response relationship. Animal regimens cannot supply that missing human evidence. MOTS-c has no FDA-approved human use and is described here as laboratory research material, not for human consumption. The existing sources also describe its prohibition in elite sport.
A controlled human treatment trial, with close attention to baseline illness, could test the unresolved question: what happens when people are given extra MOTS-c? The dialysis measurement makes that question more urgent. It does not answer it.